Ibj.com

Prices for obesity drugs fall, but affordability still out of reach for many

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...
The Motley Fool

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.

Shares of Viking Therapeutics soared last year on high hopes for its obesity drug VK2735. The stock stumbled beginning in November of last year, however, seemingly on concerns over manufacturing costs ...
WVEC

Even as prices drop, it's difficult to keep up with demand for new obesity drugs

WASHINGTON — Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for ...
Los Angeles Times

Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...
Forbes

TrumpRx Has Signed Deals With Nearly Every Major Drugmaker. Are Prices Actually Falling?

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz speaks as U.S.
AOL

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.

Any investor who owned Viking Therapeutics (NASDAQ: VKTX) before November of last year is sure to be disappointed and maybe even a little worried. Shares are down nearly 60% since October last year ...